Myriad Genetics (MYGN) Non-Current Debt (2020 - 2026)

Myriad Genetics has disclosed Non-Current Debt across 5 years of filings, most recently posting $120.3 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 102.87% year-over-year to $120.3 million; the TTM figure through Mar 2026 stood at $120.3 million (up 102.87% YoY), while the FY2025 annual figure was $119.9 million, up 202.78% from the prior year.
• Non-Current Debt held at $120.3 million in Q1 2026, from $119.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for MYGN reached as high as $120.3 million in Q1 2026 and fell as low as $38.4 million in Q2 2023.
• The 4-year median for Non-Current Debt is $39.0 million (2024), against an average of $62.8 million.
• Annual changes were most pronounced in 2024 — Non-Current Debt climbed 1.04% — and 2025, when it jumped 206.41%.
• A 4-year view of Non-Current Debt shows it stood at $38.5 million in 2023, then climbed by 2.86% to $39.6 million in 2024, then jumped by 202.78% to $119.9 million in 2025, then increased by 0.33% to $120.3 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $120.3 million, $119.9 million, and $119.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.